Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness
Authors: Michelle Clark, Sarah Visintini

Cite As: Off-Label Use of Intravenous Immunoglobulin for Solid Organ Transplant Rejection, Paraneoplastic Disorders, or Recurrent Miscarriage: Clinical Effectiveness. Ottawa: CADTH; 2017 Nov. (CADTH rapid response report: summary of abstracts).

Acknowledgments:

Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners’ own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada’s federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user’s own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

About CADTH: CADTH is an independent, not-for-profit organization responsible for providing Canada’s health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.
Research Questions

What is the clinical effectiveness of the off-label use of intravenous immunoglobulin for the treatment of solid organ transplant rejection, paraneoplastic disorders, or recurrent miscarriage?

Key Findings

Five systematic reviews, three randomized controlled trials, and nine non-randomized studies were identified regarding the off-label use of intravenous immunoglobulin for the treatment of solid organ transplant rejection, paraneoplastic disorders, or recurrent miscarriage.

Methods

A limited literature search was conducted on key resources including PubMed, The Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. Methodological filters were applied to limit retrieval to health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, and non-randomized studies. Where possible, retrieval was limited to the human population. The search was also limited to English language documents published between January 1, 2012 and October 26, 2017. Internet links were provided, where available.

Selection Criteria

One reviewer screened citations and selected studies based on the inclusion criteria presented in Table 1.

Table 1: Selection Criteria

<table>
<thead>
<tr>
<th>Population</th>
<th>Patients any age with the following conditions that are not approved indications for IVIG:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Acute rejection and antibody-mediated rejection resistant to steroids after solid organ transplantation</td>
</tr>
<tr>
<td></td>
<td>- Paraneoplastic disorders (non-neurology-related)</td>
</tr>
<tr>
<td></td>
<td>- Recurrent miscarriage</td>
</tr>
<tr>
<td>Intervention</td>
<td>Human IVIG or SCIG products, including but not limited to those available in Canada, alone or in combination with corticosteroids or other immunomodulation therapy.</td>
</tr>
<tr>
<td>Comparator</td>
<td>Treatment as usual, placebo, no treatment</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Clinical benefits and harms</td>
</tr>
<tr>
<td>Study Designs</td>
<td>Health technology assessments, systematic reviews, meta-analyses, randomized controlled trials, non-randomized studies</td>
</tr>
</tbody>
</table>
Results

Rapid Response reports are organized so that the higher quality evidence is presented first. Therefore, health technology assessment reports, systematic reviews, and meta-analyses are presented first. These are followed by randomized controlled trials, and non-randomized studies.

Five systematic reviews, three randomized controlled trials, and nine non-randomized studies were identified regarding the off-label use of intravenous immunoglobulin for the treatment of solid organ transplant rejection, paraneoplastic disorders, or recurrent miscarriage. No relevant health technology assessments were identified.

Additional references of potential interest are provided in the appendix.

Overall Summary of Findings

One systematic review\(^1\) examined the use of intravenous immunoglobulin (IVIG) for the management of paraneoplastic dermatomyositis but did not report any results in the abstract. Four systematic reviews,\(^2,5\) three randomized controlled trials,\(^6-8\) five prospective observational studies,\(^9-13\) and four retrospective non-randomized studies\(^14-17\) were identified examining the use of IVIG for recurrent miscarriage. The results of the studies were varied and are presented in further detail in Table 2. No studies examining acute rejection and antibody-mediated rejection resistant to steroids after solid organ transplantation were identified.

Table 2: Summary of Included Studies

<table>
<thead>
<tr>
<th>First Author, Year</th>
<th>Indication</th>
<th>Population</th>
<th>Results</th>
<th>Authors’ Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zerdes (2017)(^1)</td>
<td>Paraneoplastic dermatomyositis</td>
<td>Not specified in the abstract</td>
<td>Not reported in the abstract</td>
<td>The authors indicated that IVIG might be a treatment alternative for patients resistant to steroids.</td>
</tr>
<tr>
<td>Mekinian (2016)(\text{c})</td>
<td>Recurrent miscarriage and implantation failures</td>
<td>Women who had experienced ≥3 miscarriages</td>
<td>Patients treated with TNF-alpha antagonists + low-dose aspirin, heparin and IVIG had live births of 71% vs 19% with aspirin + heparin</td>
<td>No specific conclusion regarding IVIG was presented in the abstract.</td>
</tr>
<tr>
<td>Wang (2016)(^9)</td>
<td>Unexplained recurrent spontaneous abortion</td>
<td>Not specified in the abstract</td>
<td>More live births were reported with IVIG than placebo, but the difference was not significant</td>
<td>The authors concluded that IVIG may be a beneficial treatment option but there is not enough evidence to support a definitive conclusion.</td>
</tr>
<tr>
<td>First Author, Year</td>
<td>Indication</td>
<td>Population</td>
<td>Results</td>
<td>Authors’ Conclusions</td>
</tr>
<tr>
<td>-------------------</td>
<td>----------------------------------</td>
<td>--------------------------------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| Egerup (2015)*    | Recurrent miscarriage            | Not specified in the abstract  | • No significant difference in live births was found between IVIG, placebo, or usual care  
• The risk of AEs appeared to increase with IVIG vs placebo | The authors concluded that they could not recommend IVIG for recurrent miscarriage. |
| Wong (2014)*      | Recurrent miscarriage            | Not specified in the abstract  | There was no significant difference in live births between IVIG and control groups | The authors concluded that IVIG was not beneficial in improving live birth rate.     |

**Randomized Controlled Trials**

<table>
<thead>
<tr>
<th>First Author, Year</th>
<th>Indication</th>
<th>Population</th>
<th>Results</th>
<th>Authors’ Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meng (2016)*</td>
<td>Unexplained recurrent spontaneous abortion</td>
<td>Not specified in the abstract</td>
<td>There were no significant differences in successful pregnancy between the IVIG and intralipid groups</td>
<td>The authors concluded that intralipid may be used as an alternative to IVIG for unexplained recurrent spontaneous abortion.</td>
</tr>
</tbody>
</table>
| Christiansen (2015)† | Secondary recurrent miscarriage | Women with unexplained secondary recurrent miscarriage and ≥4 miscarriages | • Live birth rates were not significantly different between IVIG and placebo groups  
• Median gestational length was higher for IVIG but mean birthweight was not significantly increased | The authors concluded IVIG could not be recommended for the treatment of secondary recurrent miscarriage. |
| Nazari (2015)*    | Recurrent abortion with unknown etiology | Not specified in the abstract  | There was no significant difference in live births or abortion in the IVIG vs the enoxaparin + aspirin group | The authors concluded that the lower cost combination of enoxaparin + aspirin may be an appropriate substitution for IVIG in these patients. |

**Prospective Observational Studies**

<table>
<thead>
<tr>
<th>First Author, Year</th>
<th>Indication</th>
<th>Population</th>
<th>Results</th>
<th>Authors’ Conclusions</th>
</tr>
</thead>
</table>
| Ahmadi (2017)*    | Recurrent miscarriage            | Pregnant women with recurrent miscarriage | • Th17 cells were down-regulated and Treg cells were up-regulated significantly in the IVIG group vs placebo  
• Live births were not significantly different between groups | The authors concluded that IVIG used for women with recurrent miscarriage influences the Th17/Treg ratio in peripheral blood. |
<table>
<thead>
<tr>
<th>First Author, Year</th>
<th>Indication</th>
<th>Population</th>
<th>Results</th>
<th>Authors’ Conclusions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Manfredi (2015)</td>
<td>Recurrent spontaneous abortions</td>
<td>Women with IgG subclass deficiency</td>
<td>Successful pregnancy rate was &gt;90% in the IgG group treated with IVIG</td>
<td>The authors concluded that IVIG was the only successful treatment for these patients. Identifying patients with IgG deficiencies may help target patients who will benefit from IVIG.</td>
</tr>
</tbody>
</table>
| Yamada (2015)     | Recurrent miscarriage | Women who had experienced ≥6 miscarriages | • Live birth rate was 30.8%  
• Rate of reduction of NK cell activity was greater in the group with successful pregnancies | The authors did not provide an overall conclusion regarding IVIG in the abstract. |
| Ramos-Medina (2014) | Recurrent reproductive failure | Women with recurrent reproductive failure with NK or NKT-like expansion | Live birth rate was significantly improved in the IVIG group vs no treatment group (96.3% vs 30.6%) | The authors concluded that clinical pregnancy and live birth rates were improved with IVIG in these patients. |
| Moraru (2012)     | Recurrent reproductive failure | Women with recurrent reproductive failure and expanded CD56(+) cells | • Pregnancy and live birth rates were significantly greater in the IVIG vs those without.  
• After 3 cycles of IVIG, NK cell percentages decreased significantly | The authors concluded that IVIG was safe and effective for these women. |
| Lee (2016)        | Recurrent pregnancy loss | Women who had experienced ≥2 miscarriages, with or without cellular immune abnormality | • No significant difference in live birth rates in women with or without cellular immune abnormality  
• No significant difference in success rates between groups with cellular immune abnormality | The authors concluded that IVIG was likely to be clinically effective for women with cellular immune abnormality and recurrent pregnancy loss. |
| Cohen (2015)      | Recurrent miscarriage | Women who had experienced recurrent miscarriage (average = 5) and elevated NK cells | • 86.7% of women became pregnant  
• 82.0% had a live birth | The authors concluded that low-dose IVIG therapy was effective for women with immunologic abortion and elevated NK cells. |
<table>
<thead>
<tr>
<th>First Author, Year</th>
<th>Indication</th>
<th>Population</th>
<th>Results</th>
<th>Authors’ Conclusions</th>
</tr>
</thead>
</table>
| Nyborg (2014) † ‡ | Recurrent miscarriage and implantation failure | Women who had experienced ≥3 consecutive pregnancy loses after ART | • 36.5% of patients had a live birth after first ET with IVIG + prednisone  
• Cumulative live-birth rate was 61.5% | The authors concluded that IVIG + prednisone was a promising treatment for these women but further placebo controlled trials were required. |
| Coulam (2012) † ‡ | Reproductive failure | Women who had experienced reproductive failure with elevated NK cells | No difference was observed between IVIG and intralipid for women with recurrent implantation failure and elevated NK cell activity |

AE = adverse events; ART = assisted reproductive technology; IVIG = intravenous immunoglobulin; NK = natural killer; NKT = natural killer T; vs = versus

**References Summarized**

**Health Technology Assessments**

No literature identified.

**Systematic Reviews and Meta-analyses**


Randomized Controlled Trials


Non-Randomized Studies

Prospective Observational Studies


Retrospective Observational Studies


Appendix — Further Information

Previous CADTH Reports


Randomized Controlled Trials – Steroid Resistance not Specified in Abstract


Non-Randomized Studies – Steroid Resistance not Specified in Abstract


Case Studies and Case Series


Review Articles